OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Clinical Oncology is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Influence of widely targeted quantitative lipidomics on plasma lipid predictors and pathway dysregulation for nasopharyngeal carcinoma.	861
The association of progesterone receptor and abnormal p53 expression in endometrioid endometrial cancer.	811
Knowledge and use of different breast cancer screening tools among primary care physicians: A cross-sectional study.	640
Beyond the binary: Analysis of esophageal cancer hospitalizations in the transgender population, a national inpatient sample study.	583
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.	580
Influence of chromatin remodeling molecule ARID1A on metastatic heterogeneity in triple negative breast cancer: Binding of YAP.	556
A deep learning model for the prediction of microsatellite instability and pathogenic POLE mutations in colorectal cancer using histopathologic images.	545
Integrated clinico-genomic characterization of pancreatic ductal adenocarcinoma in an Asian population.	529
Comparison of real-world outcomes over time in a large population-based cohort of patients with metastatic breast cancer.	489
Representativeness of patients with lung cancer in an integrated health care delivery system.	461
The molecular signature of gain-of-function (GOF) vs. non-GOF classification TP53 mutations in colorectal cancer.	452
Reevaluating the role of adjuvant chemotherapy in early-stage, resectable NSCLC with high-risk clinical and pathologic features.	422
Outcomes of renal function and efficacy in patients with muscle invasive bladder cancer treated by tislelizumab-based immunochemotherapy.	417
Construction of a prognostic hierarchical model for patients with HER2 positive breast cancer with brain metastases.	413
Attachment avoidance and anxiety impacting dyadic coping and communication in patients with metastatic sarcoma and their family caregivers.	390
Incidence of solid malignancies (SM) among patients with Waldenström macroglobulinemia (WM): Analysis of the SEER database (2000-2019).	390
Early integration of exercise into breast cancer care: The MSK healthy living program.	389
Comparison of diversity across real-world evidence, randomized clinical trial, and Surveillance, Epidemiology, and End Results (SEER) data in patients with metastatic breast cancer.	386
Impact of economic inequality on Kaposi sarcoma of the lung: A retrospective cohort.	373
Information and decisional needs of patients (pts) with newly diagnosed advanced cancer in the hospital: A multi-level, mixed-methods study.	349
Cascade genetic testing (CGT) female first-degree relatives (FDR) of men with germline BRCA2 mutations (gBRCA2mut) and prostate cancer (PCa): A cost-effectiveness analysis.	346
Efficacy and safety of penpulimab-containing regimens for advanced malignant solid tumors that have failed immunotherapy: A real-world study.	338
Five-year overall survival with S-1 plus docetaxel as adjuvant treatment in curatively resected pStage III gastric cancer in JACCRO GC-07.	336
Outcomes and safety of subsequent treatments after immune- and anti-VEGF therapy in patients with metastatic clear-cell renal cell carcinoma: Outcomes from a tertiary referral hospital.	335
Leadership knowledge and beliefs regarding diversity, equity, and inclusion at SWOG Cancer Research Network.	327

Impact of overfixation on actionable biomarkers and checkpoint inhibitor (CKI) targets with immunohistochemistry (IHC) in a patient population with non-small cell lung cancer (NSCLC).	326
Multi-omics study of the genomic features and clinical characteristics of hepatic sarcomatoid carcinoma located at different sites.	304
Clinical validation of next-generation sequencing-based clonality assays for minimal residual disease tracking in multiple myeloma.	303
Body image disturbances in adolescent and young adult patients with cancer confronting infertility risk and fertility preservation decisions.	298
Sun exposure and associated risks: Insight from an international survey with a focus on the organ transplant recipient population.	296
Is Medicare Advantage associated with more favorable health care access, acute care utilization, and affordability among beneficiaries with cancer?	296
Enhancing patient clinical streamlining (EPACS) pilot in the breast medicine service at memorial sloan kettering cancer center.	292
Real-world, single-center experience on the outcomes of neoadjuvant chemotherapy and trastuzumab alone or in combination with pertuzumab in human epidermal growth factor receptor-2 breast cancer patie	289
IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NS	283
Adjuvant systemic chemotherapy with or without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastases resection (HARVEST): A prospective, randomized controll	282
Arterial chemotherapy in advanced hepatocellular carcinoma: An evolutionary trajectory exploration and pooled outcome analysis.	277
Influence of high COL19A1 expression on the effectiveness of neoadjuvant immunotherapy plus chemotherapy and long-term survival in patients with esophageal squamous cell carcinoma.	275
Reconsidering the cutoff between sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.	274
The impact of using Elsevier ClinicalPath oncology treatment pathways on survival and cost of care.	272
Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: A prospective study.	272
Impact of neighborhood deprivation on disability free survival in patients with aggressive B cell non-Hodgkin lymphoma.	271
Predicting therapy-induced cardiomyopathy in long-term survivors of childhood cancer: A report from the St. Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor Study (CCSS).	266
A national survey of current scenario and future perspectives of cancer research in Brazil.	263
The five periampullary cancers: Not just different siblings but different families—An international multicenter cohort study.	259
Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: A retrospective observational cohort study.	258
The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.	257
Impact of SARS-COV2 infection on the clinical outcomes in patients with lung cancer compared to all other cancers.	254
The efficacy and safety of anlotinib combined with bevacizumab in treatment of recurrent isocitrate dehydrogenase wildtype glioblastoma: A retrospective analysis.	253
Phase II neoadjuvant trial of albumin-bound paclitaxel, trastuzumab and pertuzumab followed by anthracycline based regimens in patients with operable HER2 positive breast cancer (OMC-BC05).	249
Outcomes of Helicobacter pylori (HP) infection in esophageal cancer (EC): A 5-year nationwide analysis.	248
Tracking MRD and neoantigen targets using a tumor-informed liquid biopsy platform in HCC patients treated with personalized cancer vaccine and pembrolizumab.	246
Ten-year outcomes of hypofractionated (45 Gy in 9 fractions) intensity-modulated radiotherapy for localized prostate cancer.	245
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer.	243
A Lasso Cox score consisting of CTLA4⁺ regulatory T cells (Treg), monocytic myeloid derived suppressor cells (M-MDSC), and CXCR3⁺ CD8⁺ T cells: Association with adjuva	235
3D genomics identifies previously unreported yet clinically actionable gene fusions and complex rearrangements in a cohort of driver-negative colorectal carcinoma tumors.	234
Comprehensive genomic profiling before the first-line setting versus after the completion of standard of care in patients with previously untreated advanced solid tumors: The prospective FIRST-Dx stud	234
Positive margin and advanced depth of invasion as the indicators for assessing the necessity of adjuvant chemoradiotherapy in early-stage oral cavity squamous cell carcinoma.	232
Clinicopathologic features and outcomes associated with induction regimen intensity among older veterans with myeloma.	228
ERBB2 (HER2) gene amplification concordance analysis of circulating tumor cells and tumor tissue in patients with breast cancer.	217
Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant.	217
A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.	216
A study on oligo-progression after durvalumab plus platinum-etoposide for ES-SCLC.	209
Incorporating long non-coding RNA (lncRNA) into genome-wide biomarker screening for prognostic gene signatures of immunotherapy outcomes.	208
Deciphering primary and acquired immunotherapy resistance with whole genome and transcriptome analysis (WGTA).	205
Concurrent EGFR wild-type tongue squamous cell carcinoma and EGFR-mutant lung adenocarcinoma and response to osimertinib.	203
Systematic high-throughput combination drug screen to enhance poly (ADP-ribose) polymerase (PARP) inhibitor efficacy in ovarian cancer.	200
Clinical and molecular Characterization of NSCLCs with MET exon 14 skipping mutation coexist MET amplification.	200
Racial and income characteristics and the burden of illness among metastatic prostate cancer patients.	194
Tp53 as a potential therapeutic biomarker in patients with recurrent high-grade glioma treated with anlotinib and temozolomide.	193
A phase I/IIa study to assess the safety, tolerability, PK, and PD of T3011, a genetically modified oncolytic virus (OVs) administered intravenously (IV) in patients with advanced solid tumors.	187
Efficacy and safety of pembrolizumab plus chemotherapy and sequential surgical resection in initial unresectable stage IIIB NSCLC.	187
Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing granulocytopenia in sarcoma patients receiving doxorubicin combined with ifosfamide: A prospective, randomized, non-inferiority phase II	186
Healthcare utilization among individuals diagnosed with hereditary breast-ovarian cancer syndrome through a universal germline genetic testing program.	186
Disease outcomes by race in patients with high-risk triple negative breast cancer with residual disease after neoadjuvant chemotherapy: A post-hoc analysis of the EA1131 randomized clinical trial.	186
The Ohio State University Guardant Shield Colorectal Cancer Screening Project.	185

Artificial neural network model analysis in T790M detection after failure of first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.	184
Association of patient and tumor characteristics with outcomes in young patients with head and neck squamous cell carcinoma (HNSCC).	184
Correlation of patient characteristics and tumor histology in patients (pts) with locally advanced cutaneous squamous cell carcinoma (LACSCC) receiving immune checkpoint inhibitor treatment (ICI): A r	184
Donafenib combined with anti-PD-1 antibody as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: A retrospective analysis.	184
The impact of COVID-19 on anxiety among breast cancer survivors before, during and after the pandemic.	183
Patterns of diversity in cancer clinical trial enrollment at a New York City academic health system, 2018-2022.	182
Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.	182
FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes.	180
A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL).	180
UCHMC 1812: A phase 1b trial of CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myeloid leukemia.	180
Sintilimab plus gemcitabine and cisplatin as a first-line treatment for patients with advanced biliary tract cancer: A biomolecular exploratory, phase II clinical trial.	180
Cancer risk assessment in patients with persistent pulmonary nodules and its correlation with cancer-free survival.	175
Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs. chemoimmunotherapy.	172
Understanding the late immune checkpoint inhibitor (ICI) symptom experience using an electronic patient reported outcomes (ePRO) app-based platform: The immunowave study.	170
Prevalence of pathogenic variants in non-BRCA genes and their impact on clinical practice in Argentina.	170
Rates of potentially actionable germline variants in homologous recombination repair genes in a large international cohort outside of the United States.	169
Safety of locally administered large surface area microparticle paclitaxel and docetaxel in combination with standard of care cancer therapies.	168
Therapeutic interchange: The cornerstone of cost effectiveness in the Oncology Care Model performance for the U.S. Oncology Network.	168
A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors.	167
Beyond gemtuzumab ozogamicin: A systematic review of antibody therapies for acute myeloid leukemia.	166
Development of a remote monitoring program for melanoma/skin oncology patients at Princess Margaret Cancer Centre.	166
The impact of virtual live education on the competence and knowledge of gynecologists caring for ovarian cancer patients.	165
Scenery of multilocus inherited neoplasia alleles syndrome (MINAS) in a single Brazilian institution.	165
A prospective exploratory clinical study of penpulimab plus anlotinib as first-line treatment for locally advanced or metastatic urothelial carcinoma.	164
Mutational profiles of sporadic synchronous colorectal cancer.	161
Clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma.	161
A real-world study of prognostic factors and risk-stratification model from Taiwanese patients with recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regi	160
Pan-Cancer analysis of the mutation frequency of genes in DDR pathway in Chinese population.	157
Evaluation of serum vascular endothelial growth factor as a biomarker in Erdheim-Chester disease.	156
A cross sectional study on female sexual function following pelvic radiotherapy.	154
Improving goal concordant care clinician workshops: Do patients benefit?	153
Hereditary cancer screening at an urban safety net hospital.	152
Filling the gap in competency-based training for medical oncology with supervised online patient counseling: A qualitative study.	152
Low baseline vitamin D levels correlate with adverse pathological features and clinical outcomes among patients with breast cancer.	151
Associations between genomic instability score (GIS), molecular characterization, and clinical outcomes in high grade serous ovarian cancers (HGSOC).	151
Participation in cancer research in BNSSG, England: A Health Equity Audit 2021.	148
Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis.	148
Impact of broadening trial eligibility criteria on the inclusion of patients with brain metastases in cancer clinical trials.	148
Gene expression correlates of adagrasib response in KRAS^G12C mutated non-small cell lung cancer (NSCLC).	147
The relationship of oncotype Dx Recurrence Score (RS) with Ki 67 in early stage breast cancer patients in a community based cancer center in rural central Nebraska.	146
Genomic characterization of papillary thyroid carcinoma in Chinese Shandong population.	146
Is recent FDA guidance on HRQoL clinical significance a barrier to clinician/patient treatment risk/benefit discussions: An example using EORTC scale endpoints in a randomized, phase 3 trial.	145
Non-invasive cell-free DNA monitoring for predicting the response to neoadjuvant immunotherapy in locally advanced esophageal squamous cell carcinoma.	144
Race- and sex-based variation in industry research and general payments to medical oncologists in the United States.	144
CD47 expression patterns in thymic epithelial tumors.	144
Characterization of patients with metastatic melanoma that relapses following complete metabolic response from anti–PD-1 therapy.	143
Financial distress, health literacy, numeracy, and treatment receipt by race/ethnicity amongst breast cancer survivors.	141
Limited benefit from the addition of immunotherapy to chemotherapy in TKI-refractory EGFR-mutant lung adenocarcinoma.	141
Genomic landscape and clonal evolution between adenocarcinoma and squamous components in adenosquamous carcinoma of the pancreas.	139
Systematic assessment of online health information related to drug therapy for non-small cell lung cancer.	138
Are we providing adequate information? patient-specific clinical trial information at NCI-designated cancer center websites.	138
Variation in survival rates among patients with angiosarcoma based on demographic and socioeconomic factors in academic versus non-academic settings: An NCDB analysis.	137
Awareness of the link between HPV, cervical cancer, and HPV vaccination: An online survey among Polish women.	137
Multi-modal single-cell profiling of sarcomas from archival tissue reveals mechanisms of resistance to immune checkpoint inhibitors.	137
Polymorphism rs4673 and plasma paraoxonase 1 level for prediction and early diagnosis of anthracycline-mediated cardiotoxicity in patients with breast cancer.	136
Randomized controlled trial (RCT) of symptom screening with targeted early palliative care (STEP) versus usual care in patients with advanced cancer.	136
Trends in the incidence of early-onset invasive colorectal cancer between 1990 and 2018, stratified by race/ethnicity, gender, and anatomic sub-sites among Pennsylvania residents.	134
Effectiveness of immunotherapy versus BRAF/MEK inhibitors in treatment-naïve BRAF-mutant advanced melanoma: A single institution retrospective analysis.	134
Tumour radiomics as imaging biomarker of tumour response to chemo-radiotherapy in patients with adenocarcinoma of rectum.	133
Adult BMI change over time and risk of colorectal adenoma.	133
A multicenter, case-control study of a novel multi-target fecal DNA test for colorectal cancer detection.	133
Vulnerable patients with metastatic colorectal cancer in a real-world setting: A multicenter retrospective study.	133
Molecular genetic sequencing of neuroendocrine tumors of the gastrointestinal tract.	132
Factors associated with weekend emergency department visits in patients with GI cancer.	132
Risk of second cancers in long term survivors of neuroendocrine tumors of the large intestine.	131
Correlation between PD-L1 high-expression and EGFR variants in non-small cell lung cancer.	131
Alternative biweekly dosing schedule of trifluridine-tipiracil (TAS-102) reduces rates of myelosuppression while maintaining therapeutic efficacy in patients (pts) with previously treated metastatic c	130
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study.	130
Survival outcomes of patients with relapsed or refractory acute myeloid leukemia after venetoclax combined with hypomethylating agents.	129
Anlotinib combined with induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A phase II study.	128
Early patient-reported outcomes are a promising predictive factor of cancer progress and outcome in older patients: The EPROFECY study.	127
Differences in clinician and patient assessment of baseline neuropathy in patients receiving taxane-based chemotherapy enrolled to SWOG S1714 (NCT# 03939481).	127
Dysregulated Th1 cells in lung squamous cell carcinoma.	126
Analysis of genomic alterations in pan-cancer from a large real-world Chinese population.	124
Tyrosine kinase inhibitors (TKIs) in trastuzumab emtansine (T-DM1) resistant HER2-positive metastatic breast cancer: A real-world study.	123
Baseline endogenous corticosteroid as a biomarker for predicting response to immune checkpoint blockade in patients with metastatic cancer.	123
A novel approach to assessing the effects of smoking on treatment response rate in muscle-invasive bladder cancer.	122
Camrelizumab plus famitinib in patients with metastatic colorectal cancer: Results from an open-label, multicenter phase II basket study.	121
The impact of COVID-19 infection on immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors.	121
Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.	120

Significance of induction chemotherapy combined with cetuximab in laryngeal preservation rate of locally advanced hypopharyngeal cancer.	118
Using variant allelic fraction of driver mutations to determine the reliability of MGMT promoter methylation testing in adult-type diffuse gliomas.	118
Using nucleosome levels, copy number alterations, and DNA methylation to profile disease state through liquid biopsy.	118
Identifying mechanisms of acquired immune escape from sequential, paired biopsies.	118
Real-world effectiveness of anlotinib plus PD-1 inhibitors as chemo-free therapy in advanced or metastatic esophageal cancer.	117
Management of residual nonretroperitoneal disease in nonseminomatous germ-cell tumors (NSGCT).	117
Pan-cancer analysis of BRAF alterations and tumor-specific mechanisms of activation.	117
Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial.	116
Estimating survival benefit of adjuvant chemotherapy in postmenopausal women with pT1-2N0 early-stage breast cancer and Oncotype DX recurrence score > 26: A National Cancer Database (NCDB) analysis	116
Chemotherapy shows better efficacy than endocrine therapy in patients with metastatic breast cancer with heterogeneous estrogen receptor expression.	116
The role of RARRES2 in regulating lipic metabolic reprogramming in the development of brain metastases in triple negative breast cancer.	116
Multimodal approach to capture spatially resolved single-cell tumor heterogeneity in breast cancer.	115
Efficacy of sacituzumab govitecan based regimen in triple-negative breast cancer: A systematic review.	115
Outcomes of classic Hodgkin lymphoma, relapsed within one year of diagnosis, in the era of novel agents.	114
Total and anatomically contextualized quantitative ¹⁸F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression-free survival in patients with prostate cancer.	114
Impact of timing of immunotherapy and cytoreductive nephrectomy on outcomes in metastatic renal cell carcinoma: Results from the CKCis database.	113
Real world evidence comparison of first-line (1L) immune-oncology(IO)/tyrosine kinase inhibitor (TKI) vs. IO/IO combination therapy in renal cell carcinoma (RCC).	113
Racial disparities in genitourinary cancer mortality trends in the United States, 2000-2020: A CDC database study.	113
Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with cabozantinib (CABO) plus durvalumab (DURVA): Preliminary analysis from the ph	112
Role of thromboprophylaxis during neoadjuvant chemotherapy before radical cystectomy in patients with bladder cancer: Results of a multicenter retrospective cohort study.	110
Improving health education through a patient-clinician partnered intervention in the patient with genitourinary cancer.	110
Patterns of early 18F-FDG PET response to nivolumab (NIVO) and ipilimumab nivolumab (IPINIVO) in patients with metastatic renal cancer (MRC).	109
Key parameters that influence surgical strategy in localised kidney cancer.	109
Short-term and long-term outcomes of transduodenal ampullectomy for patients with early ampullary cancer.	108
First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multicenter phase II trial.	108
Multi-dimensional measurements of long-term quality of life and recovery patterns of patients with cervical cancer after treatment.	107
Efficacy and safety of arterial FOLFOX chemotherapy plus anti-PD-(L)1 immunotherapy as first-line treatment for unresectable intrahepatic cholangiocarcinoma: A propensity score matched analysis.	106
Performance of the F-PSMA 1007 PET/CT for high-risk prostate cancer staging: Experience from a Latin American reference center.	106
Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study.	106
Targeting exercise and sedentary behavior for the prevention of allogeneic stem cell transplant-related cardiovascular dysfunction: The ALLO-Active trial.	105
Biomarker analysis of zanzalintinib in clear cell renal cell carcinoma from STELLAR-001.	104
Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) treated with immune checkpoint inhibitors (ICIs).	104
Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design.	104
Employing semi-quantitative methods to classify breast cancer markers (ER, PR, HER2, Ki67) expression, using the RT-qPCR based APIS Breast Cancer Subtyping Kit.	103
Analyzing the effect of treatment modalities on survival in synovial sarcoma.	103
Association of enhanced epithelial-mesenchymal transition signature with tumor microenvironment, angiogenesis, and survival in gastric cancer.	102
Identifying DNA methylation signatures in high-grade serous ovarian cancer: Results vary by control tissue type.	102
Clinical outcomes and prognostic factors in epithelial-myoepithelial carcinoma (EMC) of the breast.	101
A randomized trial of topical cannabis balms for the treatment of aromatase inhibitor–associated musculoskeletal syndrome (AIMSS).	101
STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamou	101
Clinical characteristics and outcomes of patients with metastatic colitis-associated cancer treated with EGFR inhibitors.	100
Circulating tumor DNA analysis in patients with BRAF-mutated metastatic cutaneous melanoma treated with BRAF and MEK inhibitors: Analysis of the OPTIMEL study.	100
Association of a clinical model based on skeletal muscle radiation attenuation with efficacy for patients with gastric cancer treated with chemotherapy plus PD-1 antibodies: A single-center retrospect	100
Patient characteristics, treatment patterns and early trends of lutetium Lu 177 vipivotide tetraxetan (¹⁷⁷Lu-PSMA-617) use by US urologists and oncologists.	100
Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.	99
Exploratory analysis of biomarkers of response to durvalumab in advanced HER2-negative oesophago-gastric adenocarcinoma within a phase 2 clinical trial.	99
Consistency and heterogeneity of microsatellite instability (MSI) status in paired biopsy and surgical specimens of colorectal cancer: A necessity for MSI reassessment after treatment?	98
Systematic Review on Electronic Health Interventions for Patients With Breast Cancer: Revisiting the Methodology	98
The role of exosomal LINC00853 in gastric cancer progression.	98
The power of glycobiology: Precision of polyp detection using glycoproteomic biomarkers.	98
Radiation therapy and associated cardiovascular outcomes in patients with Hodgkin’s lymphoma.	98
Immune-related adverse events in patients with gastrointestinal cancer undergoing pembrolizumab monotherapy: A systematic review of clinical trials.	97
Prognostic impact of local recurrence and timing of palliative radiotherapy in patients with unresectable recurrent rectal cancer.	97
Assessing disparities in pancreatic cancer outcomes in African Americans.	97
A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy: Results from the MD Anderson INTERCEPT Program.	97
Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors.	96
Genetic testing of Japanese patients with serrated polyposis syndrome: A multicentric study.	96
Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphom	96
Characterizing the rare abdominal neoplasms of peritoneum, retroperitoneum, and overlapping sites of peritoneum and retroperitoneum: A review of NCDB database.	96
5-hydroxymethylcytosine in cell-free DNA as liquid biomarker for immune checkpoint inhibitor therapy in non–small cell lung cancer.	95
Prognostic indicators of recurrence after surgical resection in non-pancreatic gastrointestinal neuroendocrine tumors.	95
Longitudinal changes in triceps skinfold thickness and serum albumin during chemotherapy in patients with pancreatic cancer: Gender-based prognostic insights—A prospective cohort study.	95
A phase 1, multi-center, open-label, dose-escalation, and dose-expansion study of CBP-1018, a bi-ligand-drug conjugate in patients with heavily treated advanced solid tumors.	94
Incidence of infusion related reactions of daratumumab-hyaluronidase-fihj: Pre-post intervention study of premedication omission.	94
HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIa trial.	94
Genomic and immune landscape of biliary tract cancers with ARID1A, PBRM1, and BAP1 alterations.	94
Adherence and perception of the importance of anti-COVID-19 protective measures amongst patients with cancer.	94
Percutaneous cryoablation of breast cancer metastases: Analysis of long-term single center experience, efficacy and outcomes.	94
Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study.	93
Feasibility of implementing whole genome sequencing into routine oncology care.	93
Informed decision-making about germline testing among Veterans with advanced prostate cancer (APC): A mixed-methods study.	93
Dual-agent immunotherapy for prevention of melanoma brain metastases: A real-world analysis of 8686 patients.	93
Gemcitabine/paclitaxel/adriamycin (GTA) as a nephron-sparing regimen in urothelial carcinoma: The MD Anderson Cancer Center (MDACC) experience.	93
Pelareorep driven blood TIL expansion in patients with pancreatic, breast and colon cancer.	93
The role of folate receptor-positive circulating tumor cells in the prognosis analysis of esophageal squamous cell carcinomas.	93
Real-world impact of KRAS mutations on clinical outcomes in metastatic colorectal cancer treated with trifluridine-tipiracil in the USA.	92
Relationship between immune-inflammatory markers and clinical features and deepness of tumor response and prognosis of patients with PD-L1 ≥50% metastatic NSCLC receiving first-line immunotherapy.	92
Genomic profile in Mexican women with early-stage breast cancer using Mammaprint+Blueprint assay: A retrospective study.	92
Real-world experience with CDK4/6 inhibitors in the first-line palliative setting for HR+/HER2- advanced breast cancer.	91
Effect of IL-15 on anti-tumor immune response to radio-immunotherapy through systemic immune activation.	91
Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity.	91
The influence of access to care on radiation therapy utilization among older women with breast cancer.	91
Upstream regulation of neurotransmitter signaling genes in metastatic colorectal cancer (mCRC) patients: Data from CALGB/SWOG 80405 trial (Alliance) and MONSTAR-SCREEN-2.	90
Use of Oncotype vs. Breast Cancer Index (BCI) for extended endocrine therapy decisions: A single center analysis in stage IA hormone receptor positive breast cancer.	90
Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) in patients with HR-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC) with PIK3CA mutations (m) in routine practice	90
Association of circulating T lymphocytes and their functional states with pathologic complete response (pCR) in breast cancer (BC). A prospective Italian study.	89
Use of integrated multi-omics analysis to determine antitumor efficacy of donafenib in combination with FADS2 inhibition in hepatocellular carcinoma.	89
Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2− metastatic breast cancer: A SEER-Medicare analysis.	89
Efficacy of alpelisib (ALP) + fulvestrant (FUL) with rational use of metformin (MET) in patients with HR+/HER2- advanced breast cancer (ABC).	88
Financial toxicity (FT), quality of life (QoL), and medication adherence patient-reported outcomes (PROs) in CLL on first-line (1L) oral oncolytics.	88
NSQIP audit of enhanced recovery after surgery protocols for radical cystectomy.	88
Natural language processing for automated breast cancer recurrence detection and classification in computed tomography reports.	87
Impact on biomarker documentation in community oncology by optimizing clinical decision support.	87
Predictors of response and surgical approach after neoadjuvant chemotherapy in receptor-positive/HER2-negative stage II-III breast cancer patients treated in two private cancer care centers in Lima, P	87
Effects of socioeconomic status (SES) and healthcare resource (HCR) availability on survival in Black patients (pts) versus (vs) White pts with multiple myeloma (MM): A SEER Medicare analysis.	87